Hi all,
My name is Abi, I work with the policy, evidence and influencing team at Breast Cancer Now. We are looking for people to help shape our input into the National Institute for Health and Care Excellence’s (NICE) appraisal into inavolisib (sometimes known as Itovebi) with palbociclib and fulvestrant for treating recurrent hormone receptor-positive HER2-negative PIK3CA-positive advanced breast cancer after adjuvant endocrine treatment.
We would be interested to hear from anyone who has accessed inavolisib, perhaps as part of a clinical trial. We’re also interested to hear from anyone with HR-positive, HER2-negative secondary breast cancer with a PIK3CA mutation who thinks they might have been able to benefit from this treatment.
By sharing your experience you’ll help to shape our input into NICE’s appraisal.
If you’d be happy to share your experience or thoughts, please email policy@breastcancernow.org by 5pm Friday 30th May.